AbbVie publishes pipeline presentation highlighting July 2026 R&D program updates
ABBV•AbbVie outlines mid- to late-stage R&D slate
AbbVie outlined a broad mid- to late-stage R&D slate, led by immunology expansion plans for Rinvoq, Skyrizi, lutikizumab in dermatology, lupus.
- Regulatory actions were mapped for Rinvoq in vitiligo, alopecia areata, hidradenitis suppurativa, systemic lupus erythematosus.
- Oncology priorities centered on Epkinly in first-line DLBCL, etentamig in multiple myeloma, Elahere maintenance in platinum-sensitive ovarian cancer.
- Neuroscience programs highlighted tavapadon for Parkinson’s disease, emraclidine for schizophrenia, ABBV-932 for bipolar depression, generalized anxiety disorder.
- Eye care pipeline featured ABBV-RGX-314 gene therapy readouts in wet AMD, diabetic retinopathy using suprachoroidal, subretinal delivery approaches.
